472 results
Search Results
2. KIF18A as a potential biomarker to distinguish different breast cancer subtypes based on receptor status
3. Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants
4. Relationship between oily fish intake and breast cancer based on estrogen receptor status: a Mendelian randomization study
5. The adverse outcome pathway for breast cancer: a knowledge management framework bridging biomedicine and toxicology
6. Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment
7. Methylome and transcriptome analyses reveal insights into the epigenetic basis for the good survival of hypomethylated ER-positive breast cancer subtype
8. Distinct breast cancer phenotypes in BRCA 1/2 carriers based on ER status
9. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers
10. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer
11. Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy
12. TGFα-EGFR pathway in breast carcinogenesis, association with WWOX expression and estrogen activation
13. Correlation between postoperative treatment selection and prognosis determined using the Oncotype DX® test data: a retrospective multicenter study in Japan
14. Clinical association of progesterone receptor isoform A with breast cancer metastasis consistent with its unique mechanistic role in preclinical models
15. IL-1-conferred gene expression pattern in ERα+ BCa and AR+ PCa cells is intrinsic to ERα− BCa and AR− PCa cells and promotes cell survival
16. RNA-seq from archival FFPE breast cancer samples: molecular pathway fidelity and novel discovery
17. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors
18. 2′,3′,4′-Trihydroxychalcone changes estrogen receptor α regulation of genes and breast cancer cell proliferation by a reprogramming mechanism
19. PKA phosphorylation redirects ERα to promoters of a unique gene set to induce tamoxifen resistance
20. Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer
21. Estetrol and Mammary Gland: Friends or Foes?
22. Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer
23. TFAP2C Activates CST1 Transcription to Facilitate Breast Cancer Progression and Suppress Ferroptosis
24. Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells
25. A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor κB Pathways with Hybrid Drugs for Breast Cancer Therapy
26. Twist activates miR-22 to suppress estrogen receptor alpha in breast cancer
27. Application of preoperative ultrasound features combined with clinical factors in predicting HER2-positive subtype (non-luminal) breast cancer
28. Risk factors for breast cancer development by tumor characteristics among women with benign breast disease
29. The expression of O-linked glycosyltransferase GALNT7 in breast cancer is dependent on estrogen-, progesterone-, and HER2-receptor status, with prognostic implications
30. De-differentiation in cultures of organoids from luminal-type breast cancer is restored by inhibition of NOTCH signaling
31. Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy
32. SUPT6H controls estrogen receptor activity and cellular differentiation by multiple epigenomic mechanisms
33. Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes
34. Estrogen-dependent sushi domain containing 3 regulates cytoskeleton organization and migration in breast cancer cells
35. Activation of mitogen- and stress-activated kinase 1 is required for proliferation of breast cancer cells in response to estrogens or progestins
36. LMTK3 is implicated in endocrine resistance via multiple signaling pathways
37. Combined crizotinib and endocrine drugs inhibit proliferation, migration, and colony formation of breast cancer cells via downregulation of MET and estrogen receptor
38. Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
39. Relationship between food-derived antioxidant vitamin intake and breast cancer risk: a mendelian randomized study
40. Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling
41. Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells
42. The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERα, and is an independent prognostic factor in node-negative breast cancer
43. In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells
44. Application of parametric survival analysis to women patients with breast cancer at Jimma University Medical Center
45. Genetic and clinical landscape of ER + /PR- breast cancer in China
46. Receptor conversion and survival in breast cancer liver metastases
47. Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
48. FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer
49. SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models
50. HEXIM1 is a critical determinant of the response to tamoxifen
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.